[go: up one dir, main page]

FI92825B - Förfarande för framställning av terapeutiskt användbara kromanderivat - Google Patents

Förfarande för framställning av terapeutiskt användbara kromanderivat Download PDF

Info

Publication number
FI92825B
FI92825B FI894858A FI894858A FI92825B FI 92825 B FI92825 B FI 92825B FI 894858 A FI894858 A FI 894858A FI 894858 A FI894858 A FI 894858A FI 92825 B FI92825 B FI 92825B
Authority
FI
Finland
Prior art keywords
formula
dimethyl
hydroxy
cyano
acid
Prior art date
Application number
FI894858A
Other languages
English (en)
Finnish (fi)
Other versions
FI92825C (sv
FI894858A0 (sv
Inventor
Rolf Gericke
Manfred Baumgarth
Ingeborg Lues
Rolf Bergmann
Peyer Jacques De
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of FI894858A0 publication Critical patent/FI894858A0/sv
Publication of FI92825B publication Critical patent/FI92825B/sv
Application granted granted Critical
Publication of FI92825C publication Critical patent/FI92825C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Claims (4)

1. Förfarande för framställning av terapeutiskt an-vändbara kromanderivat med formeln (I) 5 d6 n5 r» o R\ R S/ r8 Li IL -r>2 I
10 R väri var och en av R1 och R2 är oberoende av varandra A, R1 och R2 tillsammans kan vara även en alkylen med 3-6 kolatomer,
15 R3 är OH eller 0-C0A, R4 är H, R3 och R4 tillsammans betecknar även en bindning, R5 är en icke-substituerad eller med en A- eller OH-grupp substituerad pyridyl-, pyridazinyl-, pyrazinyl-, oxodihyd-20 ropyridyl- eller oxodihydropyridazinylradikal, R6 är A00C, N02 eller CN, R7 och R8 är väte och z är 0 eller S och A är en alkyl med 1-4 kolatomer, och farmaceutiskt god-. 25 tagbara syraadditionsalter därav, kännetecknat därav, att ett kroman med formeln II R7 ^0 35 väri X-Y betecknar en grupp -CH-CR8- eller CHE-CR3R8- och E är Cl, Br, I eller en reaktionsduglig förestrad OH-grupp » · < • · II 92825 25 och symbolerna R1, R2, R3, R6, R7 och R8 har i sammanband med formeln I givna betydelser, att reagera med en förening med formeln III
5 R5-ZH III väri R5 och Z har i sammanband med formeln I givna betydelser, eller med nägot reaktionsdugligt derivat därav, och/eller föreningen med formeln I, väri R3 Sr OH 10 och R4 Sr H, dehydratiseras, och/eller i föreningen med formeln I acyleras en hydroxigrupp, och/eller i föreningen med formeln I alkyleras en sekundSr kvSveatom i en heterocyklisk ring, 15 och/eller en basisk förening med formeln I omvand- las till sitt farmaceutiskt godtagbara syraadditionssalt genom behandling med en syra.
2. Förfarande enligt patentkrav 1, kSnne- t e c k n a t dSrav, att 2,2-dimetyl-4-(2-hydroxi-3-pyri-20 dyloxi)-6-cyan-3-kromanol framstSlls.
3. Förfarande enligt patentkrav 1, kSnne- t e c k n a t dSrav, att 2,2-dimetyl-4-( 6-hydroxi-3-pyri-datzinyloxi)-6-cyan-3-kromanol framstSlls.
4. Förfarande enligt patentkrav 1, kSnne-25 tecknat dSrav, att 2,2-dimetyl-4-(1,6-dihydro-l- metyl-6-oxo-3-pyridatzinyloxi)-6-cyan-3-kromanol framstSlls .
FI894858A 1988-10-14 1989-10-13 Förfarande för framställning av terapeutiskt användbara kromanderivat FI92825C (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3835011 1988-10-14
DE3835011A DE3835011A1 (de) 1988-10-14 1988-10-14 Chromanderivate

Publications (3)

Publication Number Publication Date
FI894858A0 FI894858A0 (sv) 1989-10-13
FI92825B true FI92825B (sv) 1994-09-30
FI92825C FI92825C (sv) 1995-01-10

Family

ID=6365113

Family Applications (1)

Application Number Title Priority Date Filing Date
FI894858A FI92825C (sv) 1988-10-14 1989-10-13 Förfarande för framställning av terapeutiskt användbara kromanderivat

Country Status (14)

Country Link
EP (1) EP0363883A1 (sv)
JP (1) JP2874912B2 (sv)
KR (1) KR0150780B1 (sv)
AR (1) AR247743A1 (sv)
AU (1) AU628395B2 (sv)
DE (1) DE3835011A1 (sv)
DK (1) DK511089A (sv)
FI (1) FI92825C (sv)
HU (1) HU217812B (sv)
IL (1) IL91967A0 (sv)
NO (1) NO174422C (sv)
NZ (1) NZ231000A (sv)
PT (1) PT91979B (sv)
ZA (1) ZA897783B (sv)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3726261A1 (de) * 1986-12-23 1988-07-07 Merck Patent Gmbh Chromanderivate
AU628331B2 (en) * 1988-05-06 1992-09-17 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
DE3924417A1 (de) * 1989-07-24 1991-01-31 Merck Patent Gmbh Chromanderivate
GB8924373D0 (en) * 1989-10-30 1989-12-20 Beecham Group Plc Novel compounds
DE4038752A1 (de) * 1990-12-05 1992-06-11 Merck Patent Gmbh Chromanderivate
JP3442815B2 (ja) * 1992-05-13 2003-09-02 第一製薬株式会社 ジアザビシクロアルケン誘導体
GB9316111D0 (en) * 1993-08-04 1993-09-22 Pfizer Ltd Benzopyrans
US5837702A (en) * 1993-10-07 1998-11-17 Bristol-Myers Squibb Co. 4-arylamino-benzopyran and related compounds
JP2001151767A (ja) * 1999-09-17 2001-06-05 Nissan Chem Ind Ltd ベンゾピラン誘導体
JP2001158780A (ja) * 1999-09-24 2001-06-12 Nissan Chem Ind Ltd ４−オキシベンゾピラン誘導体
JP2001172275A (ja) * 1999-10-05 2001-06-26 Nissan Chem Ind Ltd ４−オキシベンゾピラン誘導体
AU2006284860A1 (en) * 2005-09-01 2007-03-08 Janssen Pharmaceutica N.V. Benzopyran and pyranopyridine derivatives as potassium channel openers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8419515D0 (en) * 1984-07-31 1984-09-05 Beecham Group Plc Treatment
DE3726261A1 (de) * 1986-12-23 1988-07-07 Merck Patent Gmbh Chromanderivate
CH674984A5 (sv) * 1987-05-16 1990-08-15 Sandoz Ag
AU628331B2 (en) * 1988-05-06 1992-09-17 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
EP0346724A1 (de) * 1988-06-16 1989-12-20 MERCK PATENT GmbH Chromanderivate
DE3918041A1 (de) * 1989-06-02 1990-12-06 Merck Patent Gmbh Chromanderivate

Also Published As

Publication number Publication date
HU895311D0 (en) 1990-01-28
HU217812B (hu) 2000-04-28
KR0150780B1 (ko) 1998-10-15
DE3835011A1 (de) 1990-04-19
EP0363883A1 (de) 1990-04-18
JPH02145584A (ja) 1990-06-05
PT91979B (pt) 1995-05-31
IL91967A0 (en) 1990-07-12
AR247743A1 (es) 1995-03-31
NO174422B (no) 1994-01-24
ZA897783B (en) 1991-07-31
AU4256589A (en) 1990-04-26
NO894103D0 (no) 1989-10-13
PT91979A (pt) 1990-04-30
JP2874912B2 (ja) 1999-03-24
NO894103L (no) 1990-04-17
AU628395B2 (en) 1992-09-17
DK511089A (da) 1990-04-15
KR900006326A (ko) 1990-05-07
FI92825C (sv) 1995-01-10
NZ231000A (en) 1992-02-25
DK511089D0 (da) 1989-10-13
FI894858A0 (sv) 1989-10-13
NO174422C (no) 1994-05-04
HUT58082A (en) 1992-01-28

Similar Documents

Publication Publication Date Title
FI93358C (sv) Förfarande för framställning av terapeutiskt användbara kromanderivat
AU604809B2 (en) Chroman derivatives
US5387587A (en) Chroman derivatives
FI92825B (sv) Förfarande för framställning av terapeutiskt användbara kromanderivat
FI92824B (sv) Förfarande för framställning av terapeutiskt användbara kromanderivat
FI95700C (sv) Förfarande för framställning av terapeutiskt användbara kromanderivat
FI95250B (sv) Förfarande för framställning av nya, terapeutiskt användbara kromanderivat
FI95131B (sv) Förfarande för framställning av nya, terapeutiskt användbara kromanderivat
US5132307A (en) Tetralin compounds
JPH0320275A (ja) クロマン誘導体
AU645373B2 (en) Chroman derivatives
JP3468589B2 (ja) ５−アミノフラボン誘導体

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed

Owner name: MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUN